ACST Stock – (NASDAQ: ACST) is actually giving an update on the use

ACST Stock – (NASDAQ: ACST) is actually providing an update on the use

ACST
-1.84%
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is giving an update on the use of the “at the market” equity of its providing program.

As previously disclosed, Acasti entered into an amended and restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Wainwright & Co., LLC (collectively, the “Agents”), to put into practice a “at the market” equity offering system under which Acasti may well issue as well as promote from time to time the common shares of its having an aggregate offering price of up to $75 million through the Agents (the “ATM Program”).

ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the last distributions found on January 27, 2021, Acasti given an aggregate of 20,159,229 common shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$21.7 huge number of. The ATM Shares ended up being marketed at prevailing market rates averaging US$1.0747 a share. No securities were sold through the facilities of the TSXV or perhaps, to the understanding of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S-3 (No. 333-239538) as made effective on July 7, 2020, as well as the Sales Agreement. Pursuant to the Sales Agreement, a cash commission of 3.0 % on the aggregate yucky proceeds raised was given to the Agents in connection with the services of theirs. As a result of the latest ATM sales, Acasti has a total of 200,119,659 common shares issued and outstanding as of March 5, 2021.

The additional capital raised has strengthened Acasti’s balance sheet and can supply the Company with supplemental freedom in its continuous review process to explore as well as evaluate strategic alternatives.

Approximately Acasti – ACST Stock

Acasti is a biopharmaceutical innovator that has historically focused on the research, development and commercialization of prescribed drugs making use of OM3 greasy acids delivered both as totally free fatty acids and bound-to-phospholipid esters, produced from krill oil. OM3 fatty acids have substantial clinical evidence of efficacy as well as safety for lowering triglycerides in people with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being developed for clients with severe HTG.

Forward Looking Statements – ACST Stock

Statements in this press release which are not statements of current or historical truth constitute “forward-looking information” to the meaning of Canadian securities laws and “forward-looking statements” within the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward looking claims involve known and unknown risks, uncertainties, as well as other unknown components that might cause the particular results of Acasti to be materially different from historical outcomes and as a result of any future outcomes expressed or perhaps implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, people are actually urged to give some thought to statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or other similar expressions to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward looking statements, which speak only as of the day of this press release. Forward-looking claims in this press release include, but are not confined to, info or statements about Acasti’s strategy, succeeding operations as well as the review of its of strategic options.

The forward-looking claims found in this press release are expressly qualified in the entirety of theirs by this cautionary declaration, the “Special Note Regarding Forward Looking Statements” section in Acasti’s latest annual report on Form 10 K and quarterly report on Form 10-Q, which are readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com and also on the investor section of Acasti’s site at www.acastipharma.com. All forward looking statements in that press release are produced as of the day of this particular press release.

ACST Stock – Acasti does not undertake to update some such forward looking statements whether as a result of brand new information, future events or even otherwise, except as called for by law. The forward looking claims contained herein are also subject generally to risks and assumptions as well as uncertainties that are discussed from time to time in Acasti’s public securities filings with the Securities as well as The Canadian and exchange Commission securities commissions, like Acasti’s latest annual report on Form 10-K and quarterly report on Form 10-Q underneath the caption “Risk Factors“.

 

ACST Stock – (NASDAQ: ACST) is actually giving an update on the use

Comments are Disabled